VCM
ACAD icon

Violich Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Violich Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-9,025
Closed -$228K – 114
2026
Q2 		$228K Hold
9,025
– – 0.02% 117
2026
Q1 		$201K Hold
9,025
– – 0.02% 118
2025
Q4 		$241K Buy
+9,025
New +$216K 0.03% 104

Other funds holding ACAD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Violich Capital Management's ACAD Position: Q3 2026 in Review

Violich Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 9,025 shares — an estimated $228K sold.

Violich Capital Management first reported a position in ACAD in Q4 2025 and held it in 3 quarters. The position peaked at $241K in Q4 2025. 179 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Violich Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Violich Capital Management sold 9,025 Acadia Pharmaceuticals shares in Q3 2026, an estimated $228K.
  • Violich Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Violich Capital Management's Acadia Pharmaceuticals position peaked at $241K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Violich Capital Management's 13F filing for Q3 2026, filed 5 Oct 2026.